Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy
← catalyst calendarNCT06360289 · readout in 483 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
346actual
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hereditary Amyloidosis, Transthyretin-Related
- Asymptomatic Carrier State
Intervention
- Other: Standard of Care
Primary outcomes
what the primary-completion date above is the date OFNfL Levels in Asymptomatic Carriers of a TTR Variant and Symptomatic hATTR Patients With Polyneuropathy at Baseline
measured Baseline
Change in NfL Levels Over Time in Asymptomatic Carriers of a TTR Variant and Symptomatic hATTR Patients With Polyneuropathy
measured Up to 24 months
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed